Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Misses on Revenue, Stock Down 1.05%

Arrowhead Pharmaceuticals reported an EPS of $-0.17, which was slightly better than expected, resulting in a positive surprise. However, the lack of revenue data and no guidance update contributed to a stock decline of 1.05%. Investors may be cautious due to the absence of additional insights from management.